IBA Successfully Concludes Litigation Over Competing Fiducial Marker
(firmenpresse) - INDIANAPOLIS, IN -- (Marketwired) -- 08/06/13 -- IBA (Ion Beam Applications S.A.) (EURONEXT BRUSSELS: IBAB), the global high-tech leader in the next generation of radiation therapy and diagnostics for the treatment of cancer, announces the execution of a Letter of Intent to resolve litigation and claims of IBA subsidiary RadioMed Corp. against ONC Solutions, Inc. RadioMed sued ONC for misappropriation of RadioMed's trade secrets and use of them to develop a competing linear fiducial marker called the X-Mark™.
RadioMed and ONC litigated their dispute through a jury trial and judgment, resulting in an award of money damages to RadioMed and an order that ONC assign to RadioMed the patent and other technical requirements for the X-Mark and X-Mark Ultra. Under the Letter of Intent, ONC expresses its intent to relinquish its right to appeal and otherwise challenge the court order, immediately assigning ONC's patent to RadioMed.
IBA's RadioMed affiliate invented, developed, and sells the VISICOIL™ line of fiducial markers. RadioMed alleged that ONC's founders misappropriated technical information and the product design from RadioMed. RadioMed's claims resulted in a jury verdict for money damages, a doubling of that award for unfair or deceptive trade practices, and a court order for return of the patent and technical data for the X-Mark. The current agreement resolves all pending litigation between the two companies.
IBA (Ion Beam Applications S.A.) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today. The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room systems.
IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
Headquartered in Belgium and employing more than 1,200 people worldwide, IBA currently has installed systems across Europe and the US and is expanding into emerging markets. The Company is focused on building sustainable global growth for investors by providing solutions in the fight against cancer.
VISICOIL is a patented (US Patent 8,027,712) helically wound gold coil available in various diameters and lengths to aid in the treatment of a range of radiation therapy techniques that target the prostate, lung, liver, pancreas, breast, and various other organs.
The clinical success of focused, dose-delivery procedures such as image guided radiation therapy (IGRT) and conformal radiation therapy (CRT) is based on the accuracy of target identification and precise patient positioning. VISICOIL's flexible coiled markers allow for accurate tumor localization, using a variety of visualization techniques. VISICOIL is a general-purpose implanted fiducial marker. The marker is indicated for use to radiographically mark soft tissue for future therapeutic procedures, per US FDA cleared 510(K). Guided by VISICOIL, over 50,000 cancer patients worldwide have been treated with radiation therapy more safely and more accurately. VISICOIL is manufactured in various diameters and lengths by RadioMed Corporation, an IBA company. For more information about VISICOIL, please visit .
IBA Successfully Concludes Litigation Over Competing Fiducial Marker:
Mike Meyer
President IBA Dosimetry Americas
3150 Stage Post Drive, Suite 110
Bartlett, TN 38133
Tel: (901) 386-2242
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.08.2013 - 10:07 Uhr
Sprache: Deutsch
News-ID 284867
Anzahl Zeichen: 0
contact information:
Town:
INDIANAPOLIS, IN
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 226 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"IBA Successfully Concludes Litigation Over Competing Fiducial Marker"
steht unter der journalistisch-redaktionellen Verantwortung von
IBA SA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
